| Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002 | 462 | 2002 |
| Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer I Sigalas, AH Calvert, JJ Anderson, DE Neal, J Lunec Nature medicine 2 (8), 912-917, 1996 | 353 | 1996 |
| Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma RJ Gilbertson, RH Perry, PJ Kelly, ADJ Pearson, J Lunec Cancer research 57 (15), 3272-3280, 1997 | 342 | 1997 |
| Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line DA Tweddle, AJ Malcolm, N Bown, ADJ Pearson, J Lunec Cancer research 61 (1), 8-13, 2001 | 213 | 2001 |
| Clinical and molecular stratification of disease risk in medulloblastoma R Gilbertson, C Wickramasinghe, R Hernan, V Balaji, D Hunt, ... British journal of cancer 85 (5), 705-712, 2001 | 200 | 2001 |
| Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay K De Preter, F Speleman, V Combaret, J Lunec, G Laureys, BHJ Eussen, ... Modern Pathology 15 (2), 159-166, 2002 | 198 | 2002 |
| The p53 pathway and its inactivation in neuroblastoma DA Tweddle, ADJ Pearson, M Haber, MD Norris, C Xue, C Flemming, ... Cancer letters 197 (1-2), 93-98, 2003 | 193 | 2003 |
| C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value JK Mellon, J Lunec, C Wright, CHW Horne, P Kelly, DE Neal The Journal of urology 155 (1), 321-326, 1996 | 192 | 1996 |
| High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastomap53/MDM2/p14ARF Pathway in Neuroblastoma J Carr-Wilkinson, K O'Toole, KM Wood, CC Challen, AG Baker, JR Board, ... Clinical cancer research 16 (4), 1108-1118, 2010 | 189 | 2010 |
| Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer NC Levitt, FALM Eskens, KJ O’Byrne, DJ Propper, LJ Denis, SJ Owen, ... Clinical Cancer Research 7 (7), 1912-1922, 2001 | 183 | 2001 |
| Small-molecule inhibitors of the MDM2-p53 protein− protein interaction based on an isoindolinone scaffold IR Hardcastle, SU Ahmed, H Atkins, G Farnie, BT Golding, RJ Griffin, ... Journal of medicinal chemistry 49 (21), 6209-6221, 2006 | 168 | 2006 |
| p53 is a direct transcriptional target of MYCN in neuroblastoma L Chen, N Iraci, S Gherardi, LD Gamble, KM Wood, G Perini, J Lunec, ... Cancer research 70 (4), 1377-1388, 2010 | 166 | 2010 |
| Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67 VM Tut, KL Braithwaite, B Angus, DE Neal, J Lunec, JK Mellon British Journal of cancer 84 (2), 270-275, 2001 | 155 | 2001 |
| Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein− protein interaction: structure− activity studies leading to improved potency IR Hardcastle, J Liu, E Valeur, A Watson, SU Ahmed, TJ Blackburn, ... Journal of medicinal chemistry 54 (5), 1233-1243, 2011 | 151 | 2011 |
| Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse J Carr, E Bell, ADJ Pearson, UR Kees, H Beris, J Lunec, DA Tweddle Cancer research 66 (4), 2138-2145, 2006 | 143 | 2006 |
| Quality assessment of genetic markers used for therapy stratification IM Ambros, J Benard, M Boavida, N Bown, H Caron, V Combaret, ... Journal of clinical oncology 21 (11), 2077-2084, 2003 | 141 | 2003 |
| MYCN oncoprotein targets and their therapeutic potential E Bell, L Chen, T Liu, GM Marshall, J Lunec, DA Tweddle Cancer letters 293 (2), 144-157, 2010 | 134 | 2010 |
| p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells DA Tweddle, AJ Malcolm, M Cole, ADJ Pearson, J Lunec The American journal of pathology 158 (6), 2067-2077, 2001 | 130 | 2001 |
| Analysis of the p53 tumor‐suppressor gene in hepatocellular carcinomas from Britain C Challen, J Lunec, W Warren, J Collier, MF Bassendine Hepatology 16 (6), 1362-1366, 1992 | 126 | 1992 |
| Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction IR Hardcastle, SU Ahmed, H Atkins, AH Calvert, NJ Curtin, G Farnie, ... Bioorganic & medicinal chemistry letters 15 (5), 1515-1520, 2005 | 122 | 2005 |
